Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience. (January 2017)

• Record Type: Journal Article
• Authors: Gerullis, Holger; Wawroschek, Friedhelm; Köhne, Claus-Henning; Ecke, Thorsten Holger
• Is Part Of: Therapeutic advances in urology. Volume 9:Number 1(2017:Jan.)
• Page Start: 28
• Page End: 35
• Publication Date: 2017-01
• Subjects: metastatic urothelial carcinoma -- second line -- mTCCU -- urothelial cancer -- vinflunine; Urology -- Periodicals; Urologic Diseases -- therapy -- Periodicals; Genital Diseases, Male -- therapy -- Periodicals; Urologie -- Périodiques; 616.6005
• DOI: 10.1177/1756287216677903
• Languages: English
• ISSNs: 1756-2872

Abstract

Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the currently available reports describe experiences with VFL in a daily clinical setting. This review gives a short overview on clinical experiences and clinical trials involving VFL since the approval of this drug in 2009.